GSK Temporarily Pulls European Application For Tafinlar/Mekinist Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK has withdrawn its application to market the combined use of Tafinlar and Mekinist in Europe after the region’s top drug regulator said more data were needed on trametinib to approve the combo’s use in melanoma. GSK will resubmit the dossier once it has further results from an ongoing Phase III clinical trial.